Charles Schwab
RARX

Charles Schwab’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Charles Schwab’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-216,524
Closed -$10.4M – 3426
2020
Q1 		$10.4M Buy
216,524
+1,835
+0.9% +$85.4K 0.01% 1429
2019
Q4 		$10.1M Buy
214,689
+6,953
+3% +$307K 0.01% 1666
2019
Q3 		$4.91M Buy
207,736
+132,216
+175% +$3.92M ﹤0.01% 1965
2019
Q2 		$2.27M Buy
75,520
+27,519
+57% +$630K ﹤0.01% 2331
2019
Q1 		$1.08M Buy
48,001
+9,491
+25% +$204K ﹤0.01% 2529
2018
Q4 		$701K Buy
38,510
+7,300
+23% +$115K ﹤0.01% 2650
2018
Q3 		$565K Buy
31,210
+7,610
+32% +$90.2K ﹤0.01% 2796
2018
Q2 		$235K Sell
23,600
-9,200
-28% -$63.5K ﹤0.01% 3042
2018
Q1 		$175K Buy
32,800
+11,000
+50% +$78.6K ﹤0.01% 3010
2017
Q4 		$186K Hold
21,800
– – ﹤0.01% 2991
2017
Q3 		$319K Hold
21,800
– – ﹤0.01% 2854
2017
Q2 		$409K Buy
21,800
+9,000
+70% +$203K ﹤0.01% 2761
2017
Q1 		$273K Hold
12,800
– – ﹤0.01% 2850
2016
Q4 		$195K Buy
+12,800
New +$174K ﹤0.01% 2969

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Charles Schwab's RARX Position: Q2 2020 in Review

Charles Schwab sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 216,524 shares — an estimated $10.4M sold.

Charles Schwab first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $10.4M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Charles Schwab reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Charles Schwab sold 216,524 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $10.4M.
  • Charles Schwab first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
  • Charles Schwab's Ra Pharmaceuticals, Inc. Common Stock position peaked at $10.4M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Charles Schwab's 13F filing for Q2 2020, filed 14 Aug 2020.